Geographic Area – Talk Bio

Lilly Commits $1.2 Billion to Expand GLP-1 Pill Manufacturing Facility in Puerto Rico

2 days ago talkbio0Tagged Carolina, eli lilly, expansion, Investments, Manufacturing, Oral Medicine, orforglipron, pharmaceutical production, Product containing glucagon-like peptide 1 receptor agonist (product), Puerto Rico, supply chain, United States

Eli Lilly; Puerto Rico; GLP-1 receptor agonist; orforglipron; manufacturing expansion; oral medicines; investment; Carolina; pharmaceutical production; U.S. supply chain

WuXi AppTec Divests China Clinical Services to Hillhouse Capital, Refocuses on Manufacturing Business

2 days ago talkbio0Tagged China, Clinical, clinical research services, CRDMO, Divestment, Hillhouse Capital, Manufacturing, WuXi, WuXi AppTec

WuXi AppTec; Hillhouse Capital; divestment; clinical research services; CRDMO; manufacturing; China; WuXi Clinical; MedKey

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

2 days ago talkbio0Tagged Direct-to-Consumer, discount, eli lilly, Glucagon-Like Peptide 1, Growth, LillyDirect, Market, Pricing, Sales - occupational activity, Sharing (Social Behavior), Walmart Pharmacy, Weight maintenance regimen, Zepbound

Zepbound; Eli Lilly; LillyDirect; direct-to-consumer; Walmart Pharmacy; GLP-1; weight management; discount pricing; market share; sales growth

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

2 days ago talkbio0Tagged Antibodies, Bispecific, biobucks, China, COPD, IL33 protein, human, Preclinical, Qyuns Therapeutics, Respiration Disorders, Roche (company), TSLP gene

Roche; Qyuns Therapeutics; bispecific antibody; COPD; preclinical; TSLP; IL-33; China biotech; biobucks; respiratory disease

United Imaging Healthcare Q3 2025 Results: Overseas Revenue Up 42% YoY

2 days ago talkbio0Tagged Global Expansion, Investments, Market, Medical Imaging, overseas, Q3, revenue growth, United Imaging Healthcare

United Imaging Healthcare; Q3 2025 results; overseas revenue growth; medical imaging; emerging markets; R&D investment; global expansion

Unlocking Japan’s Potential in Rare Disease Drug Development: Recent Progress and Challenges (2025)

5 days ago talkbio0Tagged Clinical Trials, drug lag, Drugs, Orphan, innovation, Japan, pharmaceutical partnerships, Rare Diseases, regulatory approval

rare disease; Japan; orphan drug; drug lag; innovation; regulatory approval; pharmaceutical partnerships; clinical trials

Philadelphia on Lilly’s Radar for Next Gateway Labs Site

5 days ago talkbio0Tagged Biotech Innovation, Lilly Gateway Labs, Philadelphia

Lilly Gateway Labs; Philadelphia; Biotech Innovation

METiS BioTech Announces China’s First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial

1 week ago talkbio0Tagged AiTEM, biotech, China, Clinical, Drug Formulation Process, Metis people, nanodelivery, PBA, Phase III, pseudobulbar, Pseudobulbar affect

METiS BioTech; AI; drug formulation; Phase III; pseudobulbar affect (PBA); China; nanodelivery; AiTEM; clinical milestone

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

1 week ago talkbio0Tagged Biological Factors, conditions, Dilution technique, Gross (qualifier value), Immunology, Market, Pricing, public entity, RAPT

RAPT Therapeutics; public offering; common stock; underwritten offering; biopharmaceutical; immunology; market conditions; share dilution; offering pricing; gross proceeds

Unlocking Access: Navigating Pharma’s Regulatory Crossroads – Recent Updates (2025)

2 weeks ago talkbio0Tagged Access, access strategy, Biosimilars, CRLs, drug importation, drug price, executive actions, Market, Patient access, pharmaceutical regulation, United States Food and Drug Administration

pharmaceutical regulation; market access; drug pricing; FDA transparency; biosimilars; executive actions; market access strategy; drug importation; CRLs; patient access